CMRE has published Situation épidémiologique du 18 décembre 2019. Excerpt from the Google translation:
EVOLUTION OF THE EPIDEMIC IN THE PROVINCES OF NORTH AND SOUTH KIVU AND ITURI AT 17 DECEMBER 2019
Wednesday, December 18, 2019
Since the start of the epidemic, the cumulative number of cases is 3,351, of which 3,233 are confirmed and 118 probable. In total, there were 2,217 deaths (2,099 confirmed and 118 probable) and 1,091 people healed.
• 452 suspected cases under investigation;
• 2 new confirmed cases in North Kivu, including 1 in Butembo and 1 in Mabalako;
• 3 new deaths including:
o 1 community death in Mabalako;
o 2 deaths from confirmed cases in the CTE in North Kivu in Mabalako;
• 2 cured people leaving the CTE in North Kivu in Beni;
• No health worker is among the new confirmed cases. The cumulative number of confirmed / probable cases among health workers is 164 (5% of all confirmed / probable cases), including 41 deaths,
• Butembo again notified a confirmed case after 54 days of silence. The last case was notified on October 23, 2019.
The data presented in this table are likely to change later, after in-depth investigations and after redistribution of cases and deaths in their respective health zones.
NEWS
Butembo Sub-Coordination re-reports confirmed Ebola case after 54 days
• She is a 23 year old woman, alive and unvaccinated, from the Aloya health area in Mabalako in North Kivu. She was listed as the contact for a confirmed case of December 13, 2019, whose date of onset of signs dates back to December 06, 2019. This contact had never been seen or found to be vaccinated (not vaccinated);
• This woman went to Butembo in the Vutsundo health area to visit her big sister on December 15, 2019;
• The start date for signs at her home dates back to December 11, 2019 with the exhibition period from November 24 to December 07, 2019;
• She was consulted on December 11 in a health facility not yet identified in Kantine, in Aloya to continue her treatment with the drugs provided by the home health structure from December 12 to 14, 2019;
• This woman moved to Butembo in the Vutsundo health area on December 15, where she was seen as an outpatient from December 15 to 16, 2019 at the Wasingya health post in Vutsundo in the Butembo health zone with as clinical signs anorexia, dysphagia, chest pain and myalgia;
• On December 17, there were persistent signs and she went to be consulted at another health post, notably Notre Dame de Grâce to Mama Musayi in Butembo, where the alert was launched. She was investigated and validated, but the patient refused to be transferred to the Ebola Treatment Center (CTE);
• The sample taken in this health facility returned positive for Ebola virus disease on the same day and the patient was transferred to the ETC of Butembo after reluctance was lifted;
• A total of 19 contacts were pre-listed around this woman, including 10 members of her family, 4 co-patients and 5 healthcare providers;
• As for decontamination, the patient's household and the health structure she visited in Aloya are being identified in Mabalako, on the other hand, her sister's household in Vutsundo in Butembo, Wasingya and Notre Postes de santé Dame de Grâce were decontaminated this Wednesday, December 18, 2019;
• The vaccination around this case is scheduled for Friday, December 19 in Mabalako, while in Butembo, a vaccination ring was performed on December 17, 2019.
VACCINATION
• 2,381 people were vaccinated, until December 16, 2019, with the 2nd vaccine Ad26.ZEBOV / MVA-BN-Filo (Johnson & Johnson) in the two health areas from Karisimbi to Goma;
• Since the start of vaccination on August 8, 2018 with the rVSV-ZEBOV vaccine, 257,953 people have been vaccinated;
• Approved on October 22, 2019 by the Ethics Committee of the School of Public Health at the University of Kinshasa and on October 23, 2019 by the National Ethics Committee, the second vaccine, called Ad26.ZEBOV / MVA-BN -Filo, is produced by Janssen Pharmaceuticals for Johnson & Johnson;
• This new vaccine complements the first, rVSV-ZEBOV, a vaccine used until then (since August 08, 2018) in this epidemic manufactured by the pharmaceutical group Merck, after approval by the Ethics Committee on May 20, 2018. was recently pre-qualified for certification.
ENTRY POINT SURVEILLANCE
• Since the start of the epidemic, the total number of travelers checked (temperature measurement ) at health checkpoints has been 129,849,674 ;
• To date, a total of 109 entry points (PoE) and health control points (PoC) have been established in the provinces of North Kivu and Ituri in order to protect the country's major cities and avoid the spread of the epidemic in neighboring countries.
